Background
==========

The American Psychiatric Association\'s *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*(DSM-IV), defines reading disorder (RD) as: \"\[R\]eading achievement (i.e. reading accuracy, speed, or comprehension as measured by individually administered standardized tests) that falls substantially below that expected given the individual\'s chronological age, measured intelligence, and age-appropriate education \[[@B1]\].\" While the rate of RD among all school-age children in the United States is an estimated 4% \[[@B2]\], up to nearly one-third (15%-30%) of children with a diagnosis of attention-deficit/hyperactivity disorder (ADHD) have a co-occurring diagnosis of RD \[[@B3],[@B4]\]. Research has shown that children with ADHD and co-occurring RD (ADHD+RD) exhibit both the deficits in the basic semantics of language processing associated with RD and the higher-order executive function deficits of ADHD \[[@B5]-[@B11]\].

Given the fact that ADHD and RD often co-occur, a growing body of research has examined shared pathophysiological pathways of ADHD and RD. This research has shown that the two disorders share genetic and environmental factors \[[@B12],[@B13]\], cognitive processes \[[@B14]-[@B16]\], aspects of brain anatomy and functioning \[[@B17]\], and treatment interventions \[[@B18]\]. These and other studies have also indicated that ADHD+RD may be a unique disorder with features not associated with either ADHD or RD in isolation. For example, children with ADHD and co-occurring reading or other learning disorders have certain social impairments not observed in \"pure\" ADHD or learning disorder groups, impairments that may lead to a greater likelihood of peer rejection or starting fights \[[@B19]\]. Still other literature indicates that those with ADHD and co-occurring RD or other learning disorders have more pervasive attention and visuomotor problems than those with either ADHD without learning disorders or learning disorders without ADHD \[[@B7]\].

The purpose of the present study was to better understand differences between ADHD patients with and without co-occurring RD, using two patient groups identified from a large managed care health care claims database. The primary objective was to compare these two groups on the basis of demographic characteristics, other comorbid disorders, and pharmacological treatments patterns. A secondary objective \-- recognizing that use of medical billing records is a suboptimal means of identifying children with RD \-- was to examine the prevalence of a coded diagnosis RD among ADHD patients and to compare this prevalence with other estimates of RD prevalence among ADHD patients from the literature.

Methods
=======

Data for this study came from the U.S. Thomson Reuters Marketscan^®^Research Databases. These retrospective, claims databases are fully compliant with the Health Insurance and Portability Act (HIPAA) and capture person-specific clinical utilization, expenditures, and enrollment across inpatient, outpatient, prescription drug and carve-out services from a selection of large employers, health plans, and government and public organizations. The databases link paid claims and encounter data to detailed patient information across sites and types of providers over time and include private sector health data from approximately 100 payers and more than 500 million claim records. Data examined for this study spanned the years 2005 through 2007.

To be included in this study an individual had to be identified as having either ADHD-only or ADHD+ RD. In both groups, patients had to be diagnosed with ADHD based upon the receipt of an ICD-9-CM diagnostic code of 314.00 or 314.01 in the 2006 calendar year, with the first such date identified as the index date. In addition, individuals were required to be younger than 18 at index date and to have continuous insurance coverage, including prescription benefit coverage from 12 months prior to the index date (i.e., the pre-period) through 12 months post index date (i.e., the post-period). To enhance comparability between the ADHD only and ADHD+RD cohorts, all children with a diagnosis of mental retardation (ICD-9-CM of 317.xx, 318.xx, and 319.xx), pervasive development disorder (ICD-9-CM of 299.xx), or developmental delays (ICD-9-CM of 315.4x, 315.5x, 315.8x, or 315.9x) at any time from the start of the pre-period through the end of the post-period were excluded, as these diagnoses generally preclude or complicate a diagnosis of RD.

Given the above criteria, patients were then categorized as ADHD-only or ADHD+RD. In the ADHD-only cohort, patients were excluded if they had a diagnosis of RD (based upon receipt of an ICD-9-CM diagnostic code of 315.0x) at any time from the start of the pre-period through the end of the post-period. A total of 97, 703 children met the criteria for inclusion in the ADHD-only cohort.

For inclusion in the ADHD+RD cohort, individuals had to be diagnosed with ADHD and RD during the 2006 calendar year, with the first date of either diagnosis identified as the index date. Patients with an index diagnosis of ADHD were required to have at least one diagnosis of RD over the time period from the start of the pre-period through the end of the post-period. Similarly, those whose index diagnosis was for RD were required to have at least one diagnosis of ADHD from the start of the pre-period through the end of the post period. A total of 265 individuals were included in the ADHD+RD cohort.

The analysis compared patient demographics, comorbidities, and medication use between individuals with ADHD-only and those with ADHD+RD. Patient demographics included age, sex, region of residence, type of insurance coverage, and type of ADHD (with or without hyperactivity), while comorbid conditions included a variety of neuropsychiatric and behavioral conditions. The analysis also examined both medication use and length of therapy for ADHD medications (long-acting stimulants, short-acting stimulants, and non-stimulants) and other classes of medication used to treat psychiatric disorders (anti-depressants, anti-manic agents, antipsychotics, and anxiolytics). Differences in continuous variables were examined using t-statistics, while differences in categorical variables were examined using chi-square statistics. All analyses were conducted using SAS, version 9.1, and findings of P values of \< 0.05 were considered statistically significant. As analyses were exploratory in nature, no adjustment for multiple comparisons was undertaken.

Results
=======

In this retrospective claims database, 0.27% of patients with ADHD were found to have a co-occurring RD. Patients in the ADHD-only cohort were older than those in the ADHD+RD cohort. For example, in the ADHD-only cohort, 49.1% of individuals were age 6-11 and 44.0% were age 12-17, while in the ADHD+RD cohort, these percentages were 63.8% and 33.6%, respectively. The majority of patients in both cohorts were male (71.4% and 67.5%), insured via a PPO (30.4% and 30.6%) or an HMO (30.6% and 32.8%), and diagnosed with ADHD with hyperactivity (70.5% and 70.9%). Patients in the ADHD+RD cohort were more likely to have received formal psychological testing (24.5% v 7.8%) or neuropsychological testing (5.7% v 0.9%) in a setting that is associated with insurance reimbursement, compared to patients with ADHD-only (see Table [1](#T1){ref-type="table"}).

###### 

Demographics and Patient Characteristics

  ----------------------------------------------------------------------------------
  Variable                                 ADHD Only\      ADHD + RD\         
                                           (N = 97, 703)   (N = 265)          
  ---------------------------------------- --------------- ------------ ----- ------
  Age\*                                                                       

                                                                              

   0-5                                     6708            6.9          7     2.6

                                                                              

   6-11                                    47970           49.1         169   63.8

                                                                              

   12-17                                   43025           44.0         89    33.6

                                                                              

  Sex                                                                         

                                                                              

   Male                                    69735           71.4         179   67.5

                                                                              

   Female                                  27968           28.6         86    32.5

                                                                              

  Insurance Type                                                              

                                                                              

   Comprehensive                           23216           23.8         63    23.8

                                                                              

   Health Maintenance Organization (HMO)   29880           30.6         87    32.8

                                                                              

   Point of Service (POS)                  13715           8.4          31    11.7

                                                                              

   Preferred Provider Organization (PPO)   29730           30.4         81    30.6

                                                                              

   Consumer-Driven Health Plan             685             0.7          1     0.4

                                                                              

   Missing/Unknown                         477             0.5          2     0.8

                                                                              

  U.S. Region                                                                 

                                                                              

   Northeast                               5519            5.6          20    7.5

                                                                              

   North Central                           16394           16.8         32    12.1

                                                                              

   South                                   26466           27.1         83    31.3

                                                                              

   West                                    9357            9.6          16    6.0

                                                                              

   Unknown                                 39967           40.9         114   43.0

                                                                              

  ADHD Diagnosis Type\*\*                                                     

                                                                              

   ADHD Without Mention of Hyperactivity   28830           29.5         77    29.1

                                                                              

   ADHD With Hyperactivity                 68873           70.5         188   70.9

                                                                              

  Testing\*\*\*                                                               

                                                                              

   Psychological Testing                   7665            7.8          65    24.5

                                                                              

   Neuropsychological Testing              873             0.9          15    5.7
  ----------------------------------------------------------------------------------

**\***Age measured at index date. Mean age in the ADHD cohort was 10.8 years (std dev = 3.5 years; median = 11 years). Mean age in the ADHD + RD cohort was 10.2 years (std dev = 3.2 years; median = 10 years).

\*\* Index ADHD, first ADHD in post period, or prior period diagnosis closest to the index date, in that order.

\*\*\*Psychological and Neuropsychological Testing are from prior and post periods.

Comparing comorbid conditions (at the three digit ICD-9-CM level) revealed that individuals with ADHD+RD, compared to those with ADHD-only, were more likely to be diagnosed with bipolar disorder (9.4% v 6.4%; P = 0.043), conduct disorder (15.5% v 11.2%; P = 0.030), depression (14.3% v 9.9%; P \< 0.001), and other learning disorders (12.8% v 3.3%; P \< 0.001). Examining subcategories of these comorbidities (e.g., the four digit ICD-9-CM level) revealed that children with ADHD+RD were more likely to be diagnosed with oppositional-defiant disorder (11.7% v 8.0%; P = 0.028), major depressive disorder, recurrent episode (5.3% v 3.0%; P = 0.026), and the learning disorder of developmental speech or language disorder (7.9% v 2.2%; P \< 0.0001). There was no difference in the two cohorts with regard to frequency of anxiety disorders, psychotic disorders, seizure disorders, or sleep disorders (see Table [2](#T2){ref-type="table"}).

###### 

Selected Comorbidities/Conditions

  Comorbidity             ADHD    ADHD + RD   P Value          
  ----------------------- ------- ----------- --------- ------ ----------
  Anxiety Disorders       1227    1.3         4         1.5    0.580
                                                               
  Bipolar/Mania           6244    6.4         25        9.4    0.043
                                                               
  Conduct Disturbance     10984   11.2        41        15.5   0.030
                                                               
  Depression              9653    9.9         38        14.3   0.015
                                                               
  Learning Disorders      3251    3.3         34        12.8   \< 0.001
                                                               
  Eating Disorders        134     0.1         1         0.4    0.306
                                                               
  Personality Disorders   120     0.1         0         0.0    1.000
                                                               
  Psychotic Disorders     869     0.9         5         1.9    0.085
                                                               
  Seizure Disorders       1097    1.1         5         1.9    0.239
                                                               
  Sleep Disorders         1866    1.9         1         0.4    0.069
                                                               
  Tics/Tourette\'s        689     0.7         0         0.0    0.272

All comorbidities examined from index date through end of post-period.

Based upon univariate analyses with chi-square tests for variables with counts of at least 5 and Fischer\'s exact test if any cell had less than 5 observations.

The two most commonly prescribed stimulant medications were extended release forms of amphetamine mixed salts (Adderall XR) and methylphenidate (Concerta), while atypical antipsychotics and antidepressants were the non-ADHD psychiatric medications most commonly prescribed. Relative to those with ADHD-only, children with ADHD+RD were significantly less likely to have received any stimulant medication (71.7% v 77.1%; P = 0.036). They were less likely, in particular, to have received the long-acting stimulant (Adderall XR) (23.0% v 31.6%; P = 0.003) or a short-acting amphetamine (4.9% v 9.5%; P = 0.011). There were no differences between the two cohorts with regard to the frequency of prescribing of anti-depressants, anti-manic agents, antipsychotics, or anxiolytics (see Table [3](#T3){ref-type="table"}). While the analyses revealed significant differences in the frequency of prescriptions for stimulant medications for children with ADHD+RD compared to those with ADHD-only, among those prescribed such medication there was no difference in average length of prescription over the 12 month post period. Specifically, children with ADHD-only who were prescribed a stimulant received, on average, 6.5 months of therapy, compared to an average of 6.7 months for those with ADHD+RD (P = 0.609). Similarly, there were no differences among users of medications between the two cohorts with regard to average length of therapy for non-stimulants, antidepressants, antipsychotics, or anxiolytics (see Table [4](#T4){ref-type="table"}).

###### 

Medication Use

  ADHD Medication                                                ADHD       ADHD + RD       P Value              
  -------------------------------------------------------------- ---------- --------------- ------------- ------ -------
  Long-Acting Stimulants                                                                                         
                                                                                                                 
  Adderall XR                                                    30901      31.6            61            23.0   0.003
                                                                                                                 
  Concerta                                                       30976      31.7            86            32.5   0.794
                                                                                                                 
  Daytrana                                                       2749       2.8             11            4.2    0.189
                                                                                                                 
  Focalin XR                                                     8002       8.2             30            11.3   0.064
                                                                                                                 
  Metadate CD                                                    5426       5.6             19            7.2    0.251
                                                                                                                 
  Metadate ER                                                    193        0.2             0             0.0    1.000
                                                                                                                 
  Methylin ER                                                    1083       1.1             5             1.9    0.227
                                                                                                                 
  Methylphenidate HCL ER                                         0          0.0             0             0.0    N/A
                                                                                                                 
  Methylphenidate HCL SR                                         0          0.0             0             0.0    N/A
                                                                                                                 
  Ritalin LA                                                     4574       4.7             15            5.7    0.451
                                                                                                                 
  Ritalin SR                                                     39         0.0             0             0.0    1.000
                                                                                                                 
  Vyvanse                                                        262        0.3             0             0.0    1.000
                                                                                                                 
  *Total Long-Acting*                                            69623      71.3            181           68.3   0.288
                                                                                                                 
  Short-Acting Stimulants                                                                                        
                                                                                                                 
  Adderall                                                       381        0.4             1             0.4    1.000
                                                                                                                 
  Amphetamine Salt Combo                                         9289       9.5             13            4.9    0.011
                                                                                                                 
  Amphetamine/Dextroamph                                         0          0.0             0             0.0    N/A
                                                                                                                 
  Cylert                                                         0          0.0             0             0.0    N/A
                                                                                                                 
  Desoxyn                                                        11         0.0             0             0.0    1.000
                                                                                                                 
  Dexedrine                                                      27         0.0             0             0.0    1.000
                                                                                                                 
  Dexmethylphenidate HCL                                         109        0.1             1             0.4    0.258
                                                                                                                 
  Dextroamphetamine Sulfate                                      1231       1.3             1             0.4    0.272
                                                                                                                 
  Dextrostat                                                     48         0.0             1             0.4    0.124
                                                                                                                 
  Dexampex                                                       0          0.0             0             0.0    N/A
                                                                                                                 
  Focalin                                                        3098       3.2             11            4.2    0.363
                                                                                                                 
  Methamphetamine HCL                                            0          0.0             0             0.0    N/A
                                                                                                                 
  Methylin                                                       4986       5.1             13            4.9    0.884
                                                                                                                 
  Methylphenidate HCL                                            6701       6.9             19            7.2    0.841
                                                                                                                 
  Methylphenidate Hcl SA                                         0          0.0             0             0.0    N/A
                                                                                                                 
  Pemoline                                                       10         0.0             0             0.0    1.000
                                                                                                                 
  Ritalin                                                        397        0.4             2             0.8    0.293
                                                                                                                 
  Provigil                                                       234        0.2             0             0.0    1.000
                                                                                                                 
  *Total Short-Acting*                                           22739      23.3            54            20.4   0.265
                                                                                                                 
  Total Stimulants                                               75354      77.1            190           71.7   0.036
                                                                                                                 
  Non-Stimulants                                                                                                 
                                                                                                                 
  Atomoxetine                                                    13732      14.1            34            12.8   0.567
                                                                                                                 
  Bupropion                                                      3486       3.6             10            3.8    0.857
                                                                                                                 
  Alpha 2 Agonists                                               11296      11.6            32            12.1   0.794
                                                                                                                 
  *Total Non-Stimulants*                                         25506      26.1            65            24.5   0.559
                                                                                                                 
  **Medications used to treat Other Mental Health Conditions**   **ADHD**   **ADHD + RD**   **P Value**          
                                                                                                                 
                                                                 N          \%              N             \%     
                                                                                                                 
  Anti-depressants                                                                                               
                                                                                                                 
  MAOI\'s                                                        0          0.0             0             0.0    N/A
                                                                                                                 
  Tricyclics                                                     1734       1.8             3             1.1    0.638
                                                                                                                 
  SSRI\'s                                                        9508       9.7             26            9.8    0.965
                                                                                                                 
  SNRI\'s                                                        772        0.8             1             0.4    0.729
                                                                                                                 
  Other                                                          5105       5.2             18            6.8    0.252
                                                                                                                 
  *Total Antidepressants*                                        14966      15.3            43            16.2   0.682
                                                                                                                 
  Antimanic (bipolar) agents                                     7208       7.4             21            7.9    0.734
                                                                                                                 
  Antipsychotics                                                                                                 
                                                                                                                 
  Typical                                                        444        0.5             0             0.0    0.638
                                                                                                                 
  Atypical                                                       15593      16.0            52            19.6   0.104
                                                                                                                 
  *Total Antipsychotics*                                         15703      16.1            52            19.6   0.116
                                                                                                                 
  Anxiolytics                                                                                                    
                                                                                                                 
  Benzodiazepines                                                1807       1.8             3             1.1    0.643
                                                                                                                 
  Others                                                         2388       2.4             5             1.9    0.557
                                                                                                                 
  *Total Anxiolytics*                                            3982       4.1             8             3.0    0.385

All comorbidties examined from index date through end of post-period.

Based upon univariate analyses with chi-square tests for variables with counts of at least 5 and Fischer\'s exact test if any cell had less than 5 observations.

###### 

Length of Therapy-By Medication Class

  Medication Class          ADHD    ADHD + RD   P Value                                  
  ------------------------- ------- ----------- --------- ----- ----- ----- ------ ----- -------
  Long-Acting Stimulants    69623   6.5         3.57      6.5   181   6.4   3.36   6.3   0.722
                                                                                         
  Short-Acting Stimulants   22739   4.1         3.28      3.0   54    3.2   2.88   2.0   0.053
                                                                                         
  Any Stimulant             75354   6.7         3.52      6.8   190   6.5   3.33   6.9   0.609
                                                                                         
  Non-Stimulants            25506   5.8         3.80      5.6   65    5.2   3.53   4.8   0.212
                                                                                         
  Antidepressants           14966   5.4         3.78      4.8   43    4.8   3.88   3.0   0.303
                                                                                         
  Antipsychotics            15703   6.4         3.75      6.7   52    6.3   3.67   7.3   0.863
                                                                                         
  Anxiolytics               3982    1.9         2.83      0.9   8     1.4   1.64   0.8   0.578

N is the total number of patients with non-missing days supply.

T-tests were used to examine differences in mean length of therapy between the two groups.

Discussion
==========

In contrast to the literature that suggests that RD co-occurs in 15-30% of children with ADHD \[[@B3],[@B4]\], less than 1% of children with ADHD in our study cohort were found to have a co-occurring coded diagnosis of RD. This almost certainly reflects the incomplete ascertainment of reading disorders using administrative claims data and highlights the fact that claims data can provide valid epidemiologic data only to the extent that the conditions of interest are diagnosed, managed and reimbursed in traditional medical settings. Learning disorders, including reading disorders, are typically recognized and managed in an educational rather than a medical setting, and formal assessment typically involves the services of providers not routinely covered by traditional medical insurance (i.e., educational or clinical psychologists and psychometrists, rather than psychiatrists and other physician providers). In contrast, ADHD, while often first recognized at home or in the classroom, is commonly diagnosed by physicians, at least in part because of the availability of effective pharmacological treatment options \[[@B20]\]. Consequently, it should be recognized that our results pertain to a select subset of all children with ADHD and RD, and our findings should be interpreted accordingly.

Despite this caveat, results of this analysis suggest that children with ADHD+RD may differ from those with ADHD alone in several important respects. First, a greater proportion of the ADHD+RD children were 6-11 years old relative to 12-17 years old (63.8% v 33.6%). In contrast, the ADHD-only children were nearly equally distributed in the 6-11 year old and 12-17 year old groups (49.1% v 44.0%). This difference in age distribution may reflect the fact that RD is typically identified when reading instruction begins in school, i.e., either the end of kindergarten or the beginning of first grade \[[@B1],[@B21]\], whereas ADHD requires the identification of symptoms in multiple domains of functioning (e.g., home, school) before it can be diagnosed \[[@B1]\]. Therefore, as the DSM-IV states: \"\[M\]any individuals are diagnosed \[with ADHD\] after the symptoms have been present for a number of years, especially in the case of individuals with Predominantly Inattentive Type \[[@B1]\].\" Alternatively, this age discrepancy could be a function of the non-representativeness of our ADHD+RD cohort. While we did exclude children with mental retardation, pervasive developmental disorder and other specific developmental delays, it may be the case that our ADHD+RD cohort included children with multiple and/or more complex disorders, a subset of children more likely to come to medical attention at an earlier age.

A large body of literature has provided evidence of a neurological basis for RD \[[@B22]-[@B34]\]. In the current study, a significantly higher percentage of ADHD+RD children relative to ADHD-only individuals had psychological testing (24.5% v 7.8%) and neuropsychological testing (15% v 0.9%). This finding reflects the following recent statement from the American Academy of Pediatrics et al. that: \"Reading involves the integration of multiple factors related to a person\'s experience, ability, and neurologic functioning\.... There is solid scientific evidence that supports the neurologic basis for the phonological coding deficit theory of reading disabilities \[[@B35]\].\" Including psychological or neuropsychological testing in the process of diagnosing RD is compliant with current medical guidelines, which state that, \"Children with learning disabilities should undergo assessments of their health, development, hearing, and vision and, when appropriate, medical and psychological interventions for associated and related treatable conditions \[[@B36]\].\"

This study also revealed significant differences between the ADHD+RD and ADHD-only cohorts relative to comorbidities and medication use. Consistent with previous research showing a strong association between ADHD+RD and antisocial behavioral disorders, including aggression, delinquency, oppositional defiant disorder \[[@B34],[@B37],[@B38]\], as well as between RD and internalizing psychiatric disorders, such as depression \[[@B34]\], the ADHD+RD cohort in this study had a higher rate of comorbid illness, including bipolar/mania, conduct disturbance, oppositional defiant disorder, depression, and learning disorders (see Table [2](#T2){ref-type="table"}). Parents, educators, and physicians should be watchful for signs of these disorders in children with both ADHD and RD.

Notably, although the patients with ADHD+RD in this study were more likely to be diagnosed with depression, bipolar/mania, or conduct disorder, they were no more likely to be prescribed antidepressant, anti-manic (bipolar), antipsychotic, or any other type of medication. Neither were those with ADHD+RD more likely to be prescribed any of the following non-stimulant medications used in the treatment of ADHD: atomoxetine \[[@B39],[@B40]\], tricyclic antidepressants \[[@B41]\], or bupropion \[[@B42],[@B43]\]. Moreover, relative to the ADHD-only group, the children with ADHD+RD were *less*likely to receive stimulant medication, which is also commonly prescribed for the treatment of ADHD \[[@B43]\]. Although the ADHD+RD group were less likely to be prescribed stimulant medication, those who did receive any medication had the same mean length of therapy as those in the ADHD-only cohort taking that medication (see Table [4](#T4){ref-type="table"}).

The findings of this study should be interpreted in the context of the limitations of the study design. First, the use of diagnostic codes to identify individuals is not as rigorous as formal diagnostic assessments for identifying people with ADHD or RD. Because RD may be diagnosed outside of a medical system that is associated with insurance reimbursement claims, use of such a claims database may preclude capturing a large segment of the ADHD+RD population. As mentioned above, this analysis found that less than 1% of individuals with ADHD received a diagnosis of RD, while the literature suggests that RD may co-occur in 15-30% of ADHD patients \[[@B3],[@B4]\]. In addition, the study focused exclusively on patients with medical and prescription benefit coverage. Given these limitations, the results may not be generalizeable to other populations. Third, as this study was descriptive in nature, it did not control for the impact of differences in patient characteristics (e.g., age distribution, severity of RD or ADHD, etc.) between the two cohorts of children. This limitation, in turn, precluded any inferences about causality. For example, it is possible that the ADHD+RD cohort in this study were prescribed less stimulant medication relative to the ADHD-only cohort due to the fact that they were younger; however, this hypothesis was not testable given the study design.

Additionally, the number of unique physician visits was not captured in this analysis. While it appears that children with ADHD + RD present with more medical conditions and psychiatric comorbidities compared to children with ADHD alone, this may be due in part to the fact that children with ill-defined or complex developmental disorders are seen by multiple physicians and may receive multiple \"rule out\" diagnoses before receiving an accurate and comprehensive assessment of their condition. Finally, the use of medical claims data precludes the use of patient assessments; as a result, the analysis could not examine quality of life, functioning, or any clinical outcomes.

Conclusions
===========

This retrospective, descriptive analysis revealed significant differences between children with ADHD+RD and those with ADHD-only. In this study, the cohort with ADHD+RD had a higher burden of comorbidity, including a greater likelihood of a comorbid diagnosis of bipolar/mania, conduct disturbance, oppositional defiant disorder, depression, and learning disorders. At the same time, the children with ADHD+RD were no more likely to have been prescribed antidepressant, anti-manic (bipolar), antipsychotic, or any other type of medication, and were less likely to have been prescribed stimulant medication. These findings indicate the need for further research into the epidemiology, treatment and associated outcomes for children with ADHD+RD. They also indicate that the burden of ADHD+RD is unique and substantial. The special characteristics of ADHD+RD should be considered when conducting clinical evaluations and targeted treatment approaches. All results should be interpreted cautiously given the limited ability to ascertain RD using claims data, and future research into RD should focus on developing and using more broadly representative datasets.
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